Analysts at Berenberg have raised their estimates for the global obesity market to $150 billion by 2035, up from $125 billion previously. This revision is the result of positive data on co-morbidities and advances in competing studies. Berenberg recommends buying shares of $LLY-1.1% and Zealand Pharma, while he recommends holding on to shares of $NVO+0.2%.
What are your thoughts on this change in estimates and have you invested in any of these companies?
This sector currently has great potential. However, shares in this sector are already quite expensive. I bought $NVO+0.2% and I don't regret it.
Honestly I'm not surprised this is happening People have settled down a lot in and after covid and are moving less, at least I think so. Fastfoods are still growing and more people are choosing them more often. It could be a really interesting sector.